Correlation of breast cancer risk factor with HER-2/neu protein overexpression according to menopausal and estrogen receptor status

BMC Women's Health

Volumn 5, Issue , 2005, Pages

  Tsakountakis, Nikos ^a   Sanidas, Elias ^a   Stathopoulos, Efstathios ^a   Kafousi, Maria ^a   Anogiannaki, Nektaria ^a   Georgoulias, Vasilis ^a   Tsiftsis, Dimitris D ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ABORTION; ADULT; AGE; ARTICLE; BODY MASS; BREAST CANCER; CALCULATION; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER SCREENING; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; FEMALE; GENE OVEREXPRESSION; GEOGRAPHY; GREECE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; MULTIVARIATE ANALYSIS; PATIENT REFERRAL; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PROTEIN ANALYSIS; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SPONTANEOUS ABORTION; UNIVERSITY HOSPITAL;

EID: 26844508453     PISSN: 14726874     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-5-1     Document Type: Article

References (22)

1. Callahan R: Genetic alterations in primary breast cancer. Breast Cancer Res Treat 1989, 13:191-203.
2. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ., Pouns GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992, 84:1279-1282.
3. Treurniet HF, Rookus MA, Peterse HL, Hart AA, van Leeuwen FE: Differences in breast cancer risk factors to neu (c-erbB2) protein overexpression of the breast tumor. Cancer Res 1992, 52:2344-2345.
4. Isola JL, Chu S, DeVries K, Matsumura K, Chew K, Ljung BM, Waldman FM: Genetic Alterations in ERBB2-amplified Breast Carcinomas. Clin Cancer Res 1999, 5:4140-4145.
5. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: Immunohistochemical detection of HER2/neu in patients with auxiliary lymph node negative breast carcinoma. Cancer 1995, 75:1320-1326.
6. De Potter CR: The neu-oncogene: more than a prognostic indicator? Hum Pathol 1994, 25:1264-1268.
7. Olsson H, Borg A, Ferno M, Ranstam J, Sirgurdsson H: Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst 1991, 83:1483-1487.
8. Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD: Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999, 8:413-419.
9. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET: Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 2000, 9:65-71.
10. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001, 37:347-354.
11. Murphy LC, Watson P: Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother 2002, 56:65-77.
12. Liu ET, Thor A, He M, Barcos M, Ljung BM, Benz C: The HER2 (cerbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992, 5:1027-1032.
13. Liu ET: Oncogenes, breast cancer, and chemoprevention. J Cell Biochem 1993, 17G:161-166.
14. DAKO A/S, Glostrup DK-2600 Denmark, code # K 5204 2.
15. Begg CB, Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994, 3:173-175.
16. Vlachonikolis IG, Aletra TJ, Georgoulias V: Incidence of breast cancer on Crete, 1994-1995. Eur J Cancer 2002, 38:574-577.
17. Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T: 17b-Estradiol mimics ligand activity of the c-erb B2 proto-oncogene product. Proc Natl Acad Sci 1993, 90:10803-10807.
18. De Bortoli M, Maggiora P, Capello D, Antoniotti S, Saviozzi S, Sapei ML, Dati C: Hormonal control of growth factor receptor expression. Ann N Y Acad Sci 1996, 784:336-348.
19. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidem 129(6):1120-1131.
20. Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002, 1:3-15.
21. Lippman ME, Dickson RB: Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med 1989, 62:459-480.
22. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between her-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Ca Inst 2003, 95(2):142-153.